Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors
View Patent ↗This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.
1. A peptide comprising an amino acid sequence as set forth in:
a).
CSVRQGPVQKC;
(SEQ ID NO: 1)
b).
CSSCQNSPALC;
(SEQ ID NO: 2)
c).
CQIPQRTATRC;
(SEQ ID NO: 3)
d).
CAKQRTDPGYC;
(SEQ ID NO: 4)
e).
CWMSPRHLGTC;
(SEQ ID NO: 5)
f).
CRNCTVIQFSC;
(SEQ ID NO: 6)
g).
CHYIAGTVQGC;
(SEQ ID NO: 7)
h).
CPLVSLRDHSC;
(SEQ ID NO: 8)
i).
CKQSYLHHLLC;
(SEQ ID NO: 9)
j).
CFQPLTPLCRC; or
(SEQ ID NO: 10)
k).
CQSYHELLLQC;
(SEQ ID NO: 11)
wherein the peptide binds and inhibits a Casein Kinase II (CKII) phosphorylation site.
2. A peptide according to claim 1 , wherein the peptide has a cyclic structure.
3. A peptide according to claim 2 , wherein the peptide is contained in a fusion polypeptide.
4. A peptide according to claim 1 , wherein the peptide is contained in a fusion polypeptide.
5. A pharmaceutical composition comprising
a). a peptide selected from the group consisting of
i). CSVRQGPVQKC (SEQ ID NO: 1);
ii). CSSCQNSPALC (SEQ ID NO: 2);
iii). CQIPQRTATRC (SEQ ID NO: 3);
iv). CAKQRTDPGYC (SEQ ID NO: 4);
v). CWMSPRHLGTC (SEQ ID NO: 5);
vi). CRNCTVIQFSC (SEQ ID NO: 6);
vii). CHYIAGTVQGC (SEQ ID NO: 7);
viii). CPLVSLRDHSC (SEQ ID NO: 8);
ix). CKQSYLHHLLC (SEQ ID NO: 9);
x). CFQPLTPLCRC (SEQ ID NO: 10);
xi). CQSYHELLLQC (SEQ ID NO: 11);
and
b). a pharmaceutically-acceptable carrier.
6. A pharmaceutical composition according to claim 5 , further comprising a cytokine.
7. A pharmaceutical composition according to claim 6 , wherein the cytokine is interferon (IFN).
8. A pharmaceutical composition according to claim 5 , wherein the peptide has a cyclic structure.
9. A pharmaceutical composition according to claim 8 , further comprising a cytokine.
10. A pharmaceutical composition according to claim 9 , wherein the cytokine is interferon (IFN).
11. A method for inhibiting tumor cell proliferation, comprising administering to a mammal an effective amount of a peptide comprising an amino acid sequence as set forth in:
a). CSVRQGPVQKC (SEQ ID NO: 1);
b). CSSCQNSPALC (SEQ ID NO: 2);
c). CQIPQRTATRC (SEQ ID NO: 3);
d). CAKQRTDPGYC (SEQ ID NO: 4);
e). CWMSPRHLGTC (SEQ ID NO: 5);
f). CRNCTVIQFSC (SEQ ID NO: 6);
g). CHYIAGTVQGC (SEQ ID NO: 7);
h). CPLVSLRDHSC (SEQ ID NO: 8);
i). CKQSYLHHLLC (SEQ ID NO: 9);
j). CFQPLTPLCRC (SEQ ID NO: 10); or
k). CQSYHELLLQC (SEQ ID NO: 11),
wherein the peptide binds and inhibits a Casein Kinase II (CKII) phosphorylation site.
12. A method according to claim 11 , wherein the tumor is a human papillomavirus (HPV)-associated tumor.
13. A method according to claim 11 , wherein the tumor is a premalignant human papillomavirus (HPV)-associated tumor.
14. A method according to claim 11 , further comprising administering a cytokine.
15. A method according to claim 14 , wherein the cytokine is interferon (IFN).
16. A method according to claim 11 , wherein the mammal is infected with human papillomavirus (HPV) and is resistant toward treatment with interferon (IFN).
17. A method according to claim 11 , wherein the peptide has a cyclic structure.
18. A method according to claim 17 , wherein the tumor is a human papillomavirus (HPV)-associated tumor.
19. A method according to claim 17 , wherein the tumor is a premalignant human papillomavirus (HPV)-associated tumor.
20. A method according to claim 17 , further comprising administering a cytokine.
21. A method according to claim 20 , wherein the cytokine is interferon (IFN).
22. A method according to claim 17 , wherein the mammal is infected with human papillomavirus (HPV) and is resistant toward treatment with interferon (IFN).
23. A method according to claim 11 , wherein the peptide is contained in a fusion polypeptide.
24. A method according to claim 23 , wherein the tumor is a human papillomavirus (HPV)-associated tumor.
25. A method according to claim 23 , further comprising administering a cytokine.
26. A method according to claim 25 , wherein the cytokine is interferon (IFN).
27. A method according to claim 23 , wherein the mammal is infected with human papillomavirus (HPV) and is resistant toward treatment with interferon (IFN).
28. A mammalian expression vector comprising a nucleotide sequence that encodes a peptide comprising an amino acid sequence as set forth in:
a). CSVRQGPVQKC (SEQ ID NO: 1);
b). CSSCQNSPALC (SEQ ID NO: 2);
c). CQIPQRTATRC (SEQ ID NO: 3);
d). CAKQRTDPGYC (SEQ ID NO: 4);
e). CWMSPRHLGTC (SEQ ID NO: 5);
f). CRNCTVIQFSC (SEQ ID NO: 6);
g). CHYIAGTVQGC (SEQ ID NO: 7);
h). CPLVSLRDHSC (SEQ ID NO: 8);
i). CKQSYLHHLLC (SEQ ID NO: 9);
j). CFQPLTPLCRC (SEQ ID NO: 10); or
k). CQSYHELLLQC (SEQ ID NO: 11).
29. A mammalian expression vector according to claim 28 , wherein the peptide has a cyclic nature.
30. A mammalian expression vector according to claim 28 , wherein the peptide is contained in a fusion polypeptide.